OXURION
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide, as well as other conditions, including wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
OXURION
Industry:
Biotechnology Life Science Medical
Founded:
1991-01-01
Address:
Heverlee, Vlaams-Brabant, Belgium
Country:
Belgium
Website Url:
http://www.oxurion.com
Total Employee:
51+
Status:
Active
Contact:
+32 16 75 13 10
Email Addresses:
[email protected]
Total Funding:
137.2 M EUR
Technology used in webpage:
SPF SSL By Default Microsoft Exchange Online Amazon Office 365 Mail Microsoft Microsoft Azure Network Solutions DNS Shutterstock Amazon Ireland Region
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Current Employees Featured
Stock Details
Company's stock symbol is FRA:TG4
Investors List
Epacria Capital Partners
Epacria Capital Partners investment in Post-IPO Equity - Oxurion
Bareldam
Bareldam investment in Post-IPO Equity - Oxurion
Key Employee Changes
| Date | New article |
|---|---|
| 2020-10-14 | Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer |
Official Site Inspections
http://www.oxurion.com Semrush global rank: 3.84 M Semrush visits lastest month: 3.43 K
- Host name: 16.110.212.35.bc.googleusercontent.com
- IP address: 35.212.110.16
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
Loading ... 